Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.

ABSTRACT:

Objectives

To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.

Patients and methods

Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular su

SUBMITTER: Handa N 

PROVIDER: S-EPMC12522525 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature